Instead, increased activity of ERK1/2-MKPs would be therapeutically advantageous under the conditions of RAS-ERK1/2 pathway hyperactivation in NB, especially in high-risk NB committed to undifferentiation. This evidence concerns the gene MAPK3 and neuroblastoma.